Drug Trial Radar · NCT05080361
Rechallenge of BRAF +/- MEK Inhibitors Following an Adverse Event in Patients With Cancer
Last checked: Nov 20, 2026Latest source record: Oct 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
16,000
Planned (sponsor's estimate)
Start
Jan 1, 2011
Primary completion
Mar 1, 2021
Study completion Dec 1, 2021
Sponsor
- Lead sponsor
- University Hospital, CaenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 15, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
Summary
As written by the sponsor on the registry.
Very little data are published on the safety of a rechallenge with a BRAF inhibitor or combination of BRAF and MEK inhibitor (BRAFi and MEKi) after an adverse event (AE). This study aimed at identifying the recurrence rate of the same AE after a BRAFi +/- MEKi rechallenge in patients with cancer and the factors associated to the recurrence.
Conditions
- Cancer
Interventions
BRAF inhibitorDrug
Reports of adverse events occurring in patients treated with at least one BRAFi or MEKi as reported in the individual case safety reports.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence rateTime frame: Up to the date of the individual case safety report notification in VigiBase(r), assessed up to 10 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.